News Stories

Following an October 2012 recommendation by the U.S. FDA's Endocrinologic and Metabolic Drugs Advisory Committee, the FDA has approved lomitapide for patients with homozygous FH. Lomitapide, known by the brand name Juxtapid, is produced by Aegerion Pharmaceuticals.

On Dec. 13, the European Medicines Agency announced that it failed to grant marketing approval for Kynamro (mipomersen sodium) due to concerns about its side effects. Kynamro has been in the Sanofi/Isis Pharmaceuticals pipeline as a therapy intended to treat homozygous FH. The drug is under development by Genzyme, which is owned by Sanofi. In October, the U.S. FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 9-6 in favor of the treatment. The U.S. FDA is expected make a decision on Kynamro by the end of January 2013.

Join NLA faculty as they present “Myopathy and More: Getting Statins to Work in the Real World” at the AHA Scientific Sessions in Los Angeles on Monday, November 5 from 7:30 to 8:45 a.m.  Part of the session will focus on results from the USAGE survey, the largest known consumer survey on statin adherence, which was conducted by the NLA in partnership with Kowa Pharmaceuticals and Eli Lilly & Co. NLA faculty for this AHA session include Jerome Cohen, MD; Matthew Ito, PharmD; and Paul Thompson, MD.